Global Influenza Diagnostics Market by Test Type (Molecular Diagnostics, Antigen-based Diagnostics, Serological Diagnostics); Product Type (Reagents, Instruments); Technology (PCR-Based, Immunoassay-Based, Lateral Flow Assays); End-Use Industry (Hospitals, Diagnostic Laboratories) and by Region; Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Influenza Diagnostics Market was valued at USD 5.0 Billion in 2024-e and will surpass USD 8.6 Billion by 2030; growing at a CAGR of 9.5% during 2025 - 2030.

The Influenza Diagnostics Market is a critical component in the early detection and management of influenza infections, which continue to pose significant public health risks worldwide. The market is driven by the ongoing need for rapid, accurate diagnostics that can help in the timely detection and treatment of influenza, especially during seasonal outbreaks and pandemics. Advances in diagnostic technologies, particularly molecular diagnostics and antigen-based tests, are expected to propel market growth. The market is further fueled by the growing demand for point-of-care diagnostics, the increasing awareness about influenza prevention, and the rising incidence of influenza infections globally. As healthcare systems focus on improving early diagnosis and reducing transmission, the demand for diagnostic tools and systems that offer quick, reliable results will continue to rise.

Technological advancements, such as the development of PCR-based, immunoassay-based, and lateral flow assays, have significantly improved the speed and accuracy of influenza diagnostics. These technologies enable healthcare professionals to diagnose influenza infections quickly and accurately, which is essential in providing timely treatment and reducing the spread of the virus. The influenza diagnostics market is expected to grow steadily due to these technological improvements and the increasing adoption of diagnostic solutions in hospitals, diagnostic laboratories, and other healthcare settings.

Molecular Diagnostics Are Largest Segment Due to Their High Accuracy and Sensitivity

Molecular Diagnostics, particularly PCR-based technologies, are the largest segment in the influenza diagnostics market, owing to their high accuracy, sensitivity, and ability to detect influenza viruses at early stages of infection. PCR-based diagnostics, including reverse transcription PCR (RT-PCR), can identify the viral RNA with great precision, even when the virus is present in small quantities. This makes molecular diagnostics the preferred choice for confirming influenza infections, especially during high-risk periods such as flu seasons and pandemics.

The growing demand for PCR-based testing is also driven by the need for early diagnosis and targeted treatment of influenza. The high sensitivity and specificity of PCR-based tests allow healthcare providers to differentiate between influenza and other respiratory infections, ensuring accurate treatment. As the technology continues to improve, the cost of PCR-based diagnostic tools is expected to decrease, which will likely increase their accessibility across various healthcare settings. Given the critical role of molecular diagnostics in ensuring accurate and timely diagnosis, this segment is expected to maintain its leadership in the market for influenza diagnostics.

Antigen-based Diagnostics Are Fastest Growing Segment Due to Their Cost-Effectiveness and Speed

Antigen-based Diagnostics are the fastest-growing segment in the influenza diagnostics market due to their cost-effectiveness, ease of use, and rapid results. These tests, which detect the presence of influenza antigens, can provide results within minutes, making them ideal for point-of-care testing in environments like clinics, emergency rooms, and primary care settings. The speed of antigen-based tests makes them particularly useful in situations where rapid decision-making is crucial, such as during outbreaks or in emergency medical scenarios.

Antigen-based diagnostic tests are also relatively affordable compared to molecular diagnostic methods, making them an attractive option for resource-limited settings. Although they are less sensitive than molecular tests, their ability to deliver rapid results at a low cost has made them a popular choice for routine screening, particularly in outpatient settings. As healthcare providers look for efficient and cost-effective ways to manage influenza, the adoption of antigen-based diagnostics is expected to continue growing, making this the fastest-growing segment in the market.

Hospitals Are Largest End-Use Industry Due to the Need for Comprehensive Diagnostic Solutions

Hospitals are the largest end-use industry in the influenza diagnostics market, as they require a wide range of diagnostic tools to manage and treat influenza patients. Hospitals are equipped to handle severe cases of influenza and are often the first point of contact for patients experiencing symptoms. The demand for accurate and rapid influenza diagnostics in hospitals is high, particularly in emergency departments, outpatient clinics, and intensive care units, where influenza cases need to be identified quickly to prevent complications.

Hospitals also require diagnostic solutions that can handle large volumes of testing, especially during peak flu seasons. The growing focus on improving patient outcomes, reducing hospital admissions, and preventing the spread of influenza within healthcare facilities drives the demand for influenza diagnostic tests in hospitals. With advanced diagnostic systems, hospitals can make more informed decisions about treatment and isolation measures, ultimately improving patient care. As the most comprehensive healthcare setting, hospitals remain the largest consumer of influenza diagnostic solutions.

North America Is Largest Region Due to Advanced Healthcare Infrastructure and High Incidence of Influenza

North America is the largest region in the influenza diagnostics market, primarily due to the region's advanced healthcare infrastructure, high incidence of influenza, and the strong presence of leading diagnostic companies. The United States, in particular, plays a significant role in the global demand for influenza diagnostics, driven by the high healthcare spending and adoption of advanced diagnostic technologies. Additionally, North America has a well-established regulatory framework and widespread access to diagnostic solutions, which further contribute to the region's dominance in the market.

The increasing number of influenza cases, especially during flu seasons and pandemics like COVID-19, has placed significant pressure on healthcare systems to improve diagnostic capabilities. The region's healthcare providers are increasingly adopting rapid testing solutions such as PCR-based diagnostics and antigen-based tests, which are critical in the early detection of influenza infections. With the ongoing focus on improving diagnostic accuracy and patient outcomes, North America is expected to maintain its leadership in the influenza diagnostics market.

Competitive Landscape and Leading Companies

The Influenza Diagnostics Market is highly competitive, with several leading companies at the forefront of innovation and market expansion. Prominent players in the market include Abbott Laboratories, Roche Diagnostics, BioMérieux, Thermo Fisher Scientific, and Quidel Corporation, among others. These companies are continuously advancing their product portfolios, with a focus on developing more efficient, rapid, and cost-effective diagnostic solutions for influenza.

The competitive landscape is shaped by the introduction of novel diagnostic technologies and partnerships between diagnostic companies, healthcare providers, and government organizations. Companies are investing in research and development to enhance the sensitivity, speed, and user-friendliness of influenza diagnostic tests. The increasing focus on point-of-care testing, particularly for antigen-based and molecular diagnostics, is also driving competition. As the demand for accurate and timely influenza diagnostics continues to grow, these leading companies are expected to maintain their dominance by introducing new, innovative products to meet the evolving needs of healthcare providers.

Recent Developments:

  • Thermo Fisher Scientific launched a new PCR-based influenza testing kit designed to deliver results in under an hour.
  • Abbott Laboratories received FDA approval for a rapid antigen-based influenza test that can be used at point-of-care settings.
  • Quidel Corporation announced a strategic partnership with healthcare providers to distribute their new influenza diagnostic instruments globally.
  • BioMérieux SA expanded its molecular diagnostics offerings with a new platform that integrates flu and COVID-19 testing for dual diagnostics.
  • Cepheid Inc. introduced an upgraded version of its PCR test for influenza, reducing processing time and improving accuracy.

List of Leading Companies:

  • Roche Diagnostics
  • Abbott Laboratories
  • Thermo Fisher Scientific
  • Quidel Corporation
  • Cepheid Inc.
  • BioMérieux SA
  • BD (Becton, Dickinson and Company)
  • Hologic Inc.
  • Luminex Corporation
  • Eiken Chemical Co., Ltd.
  • Meridian Bioscience, Inc.
  • A. Menarini Diagnostics
  • LabCorp (Laboratory Corporation of America Holdings)
  • DiaSorin S.p.A.
  • Beckman Coulter, Inc.

Report Scope:

Report Features

Description

Market Size (2024-e)

USD 5.0 Billion

Forecasted Value (2030)

USD 8.6 Billion

CAGR (2025 – 2030)

9.5%

Base Year for Estimation

2024-e

Historic Year

2023

Forecast Period

2025 – 2030

Report Coverage

Market Forecast, Market Dynamics, Competitive Landscape, Recent Developments

Segments Covered

Global Influenza Diagnostics Market by Test Type (Molecular Diagnostics, Antigen-based Diagnostics, Serological Diagnostics); Product Type (Reagents, Instruments); Technology (PCR-Based, Immunoassay-Based, Lateral Flow Assays); End-Use Industry (Hospitals, Diagnostic Laboratories) and by Region

Regional Analysis

North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, South Korea, Australia, India, and Rest of Asia-Pacific), Latin America (Brazil, Argentina, and Rest of Latin America), Middle East & Africa (Saudi Arabia, UAE, Rest of Middle East & Africa)

Major Companies

Roche Diagnostics, Abbott Laboratories, Thermo Fisher Scientific, Quidel Corporation, Cepheid Inc., BioMérieux SA, Hologic Inc., Luminex Corporation, Eiken Chemical Co., Ltd., Meridian Bioscience, Inc., A. Menarini Diagnostics, LabCorp (Laboratory Corporation of America Holdings), Beckman Coulter, Inc.

Customization Scope

Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements

1. Introduction

   1.1. Market Definition

   1.2. Scope of the Study

   1.3. Research Assumptions

   1.4. Study Limitations

2. Research Methodology

   2.1. Research Approach

      2.1.1. Top-Down Method

      2.1.2. Bottom-Up Method

      2.1.3. Factor Impact Analysis

  2.2. Insights & Data Collection Process

      2.2.1. Secondary Research

      2.2.2. Primary Research

   2.3. Data Mining Process

      2.3.1. Data Analysis

      2.3.2. Data Validation and Revalidation

      2.3.3. Data Triangulation

3. Executive Summary

   3.1. Major Markets & Segments

   3.2. Highest Growing Regions and Respective Countries

   3.3. Impact of Growth Drivers & Inhibitors

   3.4. Regulatory Overview by Country

4. Influenza Diagnostics Market, by Test Type (Market Size & Forecast: USD Million, 2023 – 2030)

   4.1. Molecular Diagnostics

   4.2. Antigen-based Diagnostics

   4.3. Serological Diagnostics

5. Influenza Diagnostics Market, by Product Type (Market Size & Forecast: USD Million, 2023 – 2030)

   5.1. Reagents

   5.2. Instruments

6. Influenza Diagnostics Market, by Technology (Market Size & Forecast: USD Million, 2023 – 2030)

   6.1. PCR-Based

   6.2. Immunoassay-Based

   6.3. Lateral Flow Assays

7. Influenza Diagnostics Market, by End-Use Industry (Market Size & Forecast: USD Million, 2023 – 2030)

   7.1. Hospitals

   7.2. Diagnostic Laboratories

   7.3. Others

8. Regional Analysis (Market Size & Forecast: USD Million, 2023 – 2030)

   8.1. Regional Overview

   8.2. North America

      8.2.1. Regional Trends & Growth Drivers

      8.2.2. Barriers & Challenges

      8.2.3. Opportunities

      8.2.4. Factor Impact Analysis

      8.2.5. Technology Trends

      8.2.6. North America Influenza Diagnostics Market, by Test Type

      8.2.7. North America Influenza Diagnostics Market, by Product Type

      8.2.8. North America Influenza Diagnostics Market, by Technology

      8.2.9. North America Influenza Diagnostics Market, by End-Use Industry

      8.2.10. By Country

         8.2.10.1. US

               8.2.10.1.1. US Influenza Diagnostics Market, by Test Type

               8.2.10.1.2. US Influenza Diagnostics Market, by Product Type

               8.2.10.1.3. US Influenza Diagnostics Market, by Technology

               8.2.10.1.4. US Influenza Diagnostics Market, by End-Use Industry

         8.2.10.2. Canada

         8.2.10.3. Mexico

    *Similar segmentation will be provided for each region and country

   8.3. Europe

   8.4. Asia-Pacific

   8.5. Latin America

   8.6. Middle East & Africa

9. Competitive Landscape

   9.1. Overview of the Key Players

   9.2. Competitive Ecosystem

      9.2.1. Level of Fragmentation

      9.2.2. Market Consolidation

      9.2.3. Product Innovation

   9.3. Company Share Analysis

   9.4. Company Benchmarking Matrix

      9.4.1. Strategic Overview

      9.4.2. Product Innovations

   9.5. Start-up Ecosystem

   9.6. Strategic Competitive Insights/ Customer Imperatives

   9.7. ESG Matrix/ Sustainability Matrix

   9.8. Manufacturing Network

      9.8.1. Locations

      9.8.2. Supply Chain and Logistics

      9.8.3. Product Flexibility/Customization

      9.8.4. Digital Transformation and Connectivity

      9.8.5. Environmental and Regulatory Compliance

   9.9. Technology Readiness Level Matrix

   9.10. Technology Maturity Curve

   9.11. Buying Criteria

10. Company Profiles

   10.1. Roche Diagnostics

      10.1.1. Company Overview

      10.1.2. Company Financials

      10.1.3. Product/Service Portfolio

      10.1.4. Recent Developments

      10.1.5. IMR Analysis

    *Similar information will be provided for other companies 

   10.2. Abbott Laboratories

   10.3. Thermo Fisher Scientific

   10.4. Quidel Corporation

   10.5. Cepheid Inc.

   10.6. BioMérieux SA

   10.7. BD (Becton, Dickinson and Company)

   10.8. Hologic Inc.

   10.9. Luminex Corporation

   10.10. Eiken Chemical Co., Ltd.

   10.11. Meridian Bioscience, Inc.

   10.12. A. Menarini Diagnostics

   10.13. LabCorp (Laboratory Corporation of America Holdings)

   10.14. DiaSorin S.p.A.

   10.15. Beckman Coulter, Inc.

11. Appendix

A comprehensive market research approach was employed to gather and analyze data on the Influenza Diagnostics Market. In the process, the analysis was also done to analyze the parent market and relevant adjacencies to measure the impact of them on the Influenza Diagnostics Market. The research methodology encompassed both secondary and primary research techniques, ensuring the accuracy and credibility of the findings.

Research Approach -

Secondary Research

Secondary research involved a thorough review of pertinent industry reports, journals, articles, and publications. Additionally, annual reports, press releases, and investor presentations of industry players were scrutinized to gain insights into their market positioning and strategies.

Primary Research

Primary research involved conducting in-depth interviews with industry experts, stakeholders, and market participants across the E-Waste Management ecosystem. The primary research objectives included:

  • Validating findings and assumptions derived from secondary research
  • Gathering qualitative and quantitative data on market trends, drivers, and challenges
  • Understanding the demand-side dynamics, encompassing end-users, component manufacturers, facility providers, and service providers
  • Assessing the supply-side landscape, including technological advancements and recent developments

Market Size Assessment

A combination of top-down and bottom-up approaches was utilized to analyze the overall size of the Influenza Diagnostics Market. These methods were also employed to assess the size of various subsegments within the market. The market size assessment methodology encompassed the following steps:

  1. Identification of key industry players and relevant revenues through extensive secondary research
  2. Determination of the industry's supply chain and market size, in terms of value, through primary and secondary research processes
  3. Calculation of percentage shares, splits, and breakdowns using secondary sources and verification through primary sources

Bottom Up and Top Down -

Data Triangulation

To ensure the accuracy and reliability of the market size, data triangulation was implemented. This involved cross-referencing data from various sources, including demand and supply side factors, market trends, and expert opinions. Additionally, top-down and bottom-up approaches were employed to validate the market size assessment.

NA

Please state your requirements.


I have read the Terms & Conditions and Privacy Policy. I agree to its terms.

Report Buying Options